Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 145Gastrointestinal 134Breast 94Thoracic 88Genitourinary 79Gynecologic 62Head & Neck 52Dermatologic 46Sarcoma 32CNS 28Lymphoid 12Endocrine 10Other solid neoplasm 8NET 8Other hematologic neoplasm 6Myeloid 4Plasma cell 3Other 1

Conditions

Obesity 62Neoplasms 20Overweight 18Polycystic Ovary Syndrome 11Dyspnea 10Sexual Dysfunction, Physiological 9Endometrial Neoplasms 8Breast Neoplasms 8Prostatic Neoplasms 7Motor Activity 7Hypertension 7Diabetes Mellitus, Type 2 7Depression 6Mucositis 5Metabolic Syndrome 5Diabetes Mellitus 5Constipation 5Pulmonary Disease, Chronic Obstructive 4Opioid-Induced Constipation 4Lung Neoplasms 4Heart Failure 4Coronary Disease 4Cardiovascular Diseases 4Anxiety Disorders 4Weight Loss 3Stomatitis 3Renal Insufficiency, Chronic 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pain 3Non-alcoholic Fatty Liver Disease 3

Interventions

atezolizumab 1TIC10 compound 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × Other × Clear all
NCT05542407 2026-01-29

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 1 Recruiting
58 enrolled
GynecologicOtherSarcoma

Carcinosarcoma, Disease, Neoplasm Metastasis, Obesity, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡